Mizuho Forecasts Strong Price Appreciation for Inspire Medical Systems (NYSE:INSP) Stock

Inspire Medical Systems (NYSE:INSP) had its price target lifted by equities research analysts at Mizuho from $55.00 to $65.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Mizuho’s price objective suggests a potential upside of 2.97% from the company’s current price.

A number of other brokerages have also issued reports on INSP. Summit Redstone set a $39.00 price target on Inspire Medical Systems in a research note on Friday, May 22nd. Robert W. Baird upped their price objective on Inspire Medical Systems from $54.00 to $59.00 and gave the company a “neutral” rating in a research report on Tuesday. Piper Sandler increased their target price on Inspire Medical Systems from $55.00 to $60.00 and gave the stock a “neutral” rating in a research note on Tuesday. UBS Group started coverage on Inspire Medical Systems in a research report on Tuesday, July 28th. They set a “sell” rating and a $39.00 target price for the company. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a $60.00 target price on shares of Inspire Medical Systems in a research note on Tuesday. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $72.22.

Inspire Medical Systems Trading Up 20.9%

Shares of NYSE INSP traded up $10.90 during trading hours on Tuesday, hitting $63.12. 1,361,615 shares of the company traded hands, compared to its average volume of 1,164,748. The company’s 50 day moving average price is $46.15 and its 200 day moving average price is $55.17. Inspire Medical Systems has a 12 month low of $38.91 and a 12 month high of $147.03. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of 14.03, a price-to-earnings-growth ratio of 5.08 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The company had revenue of $200.58 million for the quarter, compared to analyst estimates of $194.72 million. During the same period in the prior year, the company posted $0.45 EPS. The firm’s revenue for the quarter was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Equities analysts anticipate that Inspire Medical Systems will post 0.93 EPS for the current year.

Institutional Investors Weigh In On Inspire Medical Systems

Institutional investors and hedge funds have recently bought and sold shares of the company. Rheos Capital Works Inc. boosted its stake in Inspire Medical Systems by 124.0% in the fourth quarter. Rheos Capital Works Inc. now owns 117,400 shares of the company’s stock valued at $10,828,000 after acquiring an additional 65,000 shares in the last quarter. Bank of Nova Scotia increased its position in shares of Inspire Medical Systems by 49.8% during the first quarter. Bank of Nova Scotia now owns 60,000 shares of the company’s stock worth $3,095,000 after purchasing an additional 19,958 shares in the last quarter. M&T Bank Corp purchased a new stake in shares of Inspire Medical Systems during the 4th quarter valued at $85,871,000. Leonteq Securities AG lifted its holdings in shares of Inspire Medical Systems by 187.3% during the 1st quarter. Leonteq Securities AG now owns 22,812 shares of the company’s stock valued at $1,177,000 after purchasing an additional 14,873 shares during the last quarter. Finally, Eventide Asset Management LLC lifted its holdings in shares of Inspire Medical Systems by 71.5% during the 4th quarter. Eventide Asset Management LLC now owns 440,205 shares of the company’s stock valued at $40,601,000 after purchasing an additional 183,547 shares during the last quarter. 94.91% of the stock is owned by institutional investors.

Trending Headlines about Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. Inspire reported adjusted earnings of $0.14 per share, versus analyst expectations for a $0.24 loss, while revenue of $200.6 million topped the $194.7 million consensus estimate. Inspire Medical Systems Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management raised fiscal 2026 guidance. The company now expects earnings per share of $1.05 to $1.45, above the $0.91 consensus estimate, and revenue of $835 million to $875 million, broadly centered around Wall Street’s $848.9 million forecast. Inspire Announces Q2 Results and Raised Guidance
• Positive Sentiment: Oppenheimer upgraded INSP. The firm raised its rating from “market perform” to “outperform” and assigned an $85 price target, implying substantial upside from the recent trading level. Benzinga analyst rating report
• Neutral Sentiment: Analyst views remain mixed. Robert W. Baird increased its price target from $54 to $59 but maintained a “neutral” rating, indicating that the firm still sees limited near-term upside after the recent rally. The Fly analyst rating report
• Negative Sentiment: Underlying comparisons were weaker. Quarterly revenue declined 7.6% from the prior year, and earnings fell from $0.45 per share to $0.14, highlighting continued year-over-year pressure despite the quarterly beat. Inspire Medical Systems earnings report

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.